Armesocarb

Armesocarb (developmental code name MLR-1019), also known as (R)-mesocarb or L-mesocarb, is a selective atypical dopamine reuptake inhibitor (DRI). It is currently under development for the treatment of Parkinson's disease and sleep disorders.^[1][2]

Armesocarb

Clinical data
Other names	(R)-Mesocarb; L-Mesocarb; MLR-1019; MLR1019
Drug class	Atypical dopamine reuptake inhibitor
Identifiers
IUPAC name N-phenyl-N'-[3-[(2R)-1-phenylpropan-2-yl]oxadiazol-3-ium-5-yl]carbamimidate
CAS Number	34262-84-5
PubChem CID	7130196
ChemSpider	5473777
UNII	UMT8MP2NDU
Chemical and physical data
Formula	C18H18N4O2
Molar mass	322.368 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@H](CC1=CC=CC=C1)[N+]2=NOC(=C2)N=C(NC3=CC=CC=C3)[O-]
InChI InChI=1S/C18H18N4O2/c1-14(12-15-8-4-2-5-9-15)22-13-17(24-21-22)20-18(23)19-16-10-6-3-7-11-16/h2-11,13-14H,12H2,1H3,(H-,19,20,21,23)/t14-/m1/s1 Key:OWFUPROYPKGHMH-CQSZACIVSA-N

It is the active (R)-enantiomer of the formerly clinically used stimulant-like drug mesocarb (MLR-1017; brand name Sydnocarb).^[1][2][3]

Pharmacology

Mesocarb is known to be a highly selective DRI.^[2] However, in 2021, it was discovered that mesocarb is not a conventional DRI but acts as a dopamine transporter (DAT) allosteric modulator or non-competitive inhibitor.^[4][5][6]

In accordance with its nature as an atypical DAT blocker, the drug exhibits atypical effects compared to conventional DRIs.^[4][5][6][2] For example, mesocarb shows greater antiparkinsonian activity in animals compared to other DRIs.^[2]

Mesocarb has wakefulness-promoting effects in animals.^[2][7] Armesocarb, as the active enantiomer of mesocarb, shows greater therapeutic potency than the racemic form in animals.^[1][2][3] In contrast, the (S)- or D-enantiomer of mesocarb is virtually inactive in animal behavioral tests.^[3]

History

Armesocarb was first described in the scientific literature as an enantiopure compound by 2005 and again in 2017.^[3][2]

Clinical studies

As of April 2023, armesocarb is undergoing phase 1 clinical trials for Parkinson's disease and is in preclinical development for sleep disorders.^[1] The latter indication may specifically target excessive daytime sleepiness (EDS) in people with Parkinson's disease.^[2] Armesocarb is also in development for the treatment of levodopa-induced dyskinesia.^[8][2]

See also

• MRZ-9547 ((R)-phenylpiracetam)
• List of Russian drugs